Mark Volpe
Medical · Suffield, CTNPI 1720452527
Payments from drug & device makers
Across 1,128 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$2K
- Novo Nordisk$1K
- GSK$1K
- Pfizer$957
- Lilly USA, LLC$918
- plus $11K from 54 others
What the payments were for
- Food & beverage$21,17899%
- Education$1391%
- Other$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,331 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $99,885 |
| JardianceEmpagliflozin | 73 | $86,323 |
| EliquisApixaban | 99 | $83,619 |
| FarxigaDapagliflozin Propanediol | 47 | $62,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $43,984 |
| JanuviaSitagliptin Phosphate | 30 | $27,879 |
| MounjaroTirzepatide | 19 | $22,435 |
| XareltoRivaroxaban | 17 | $17,453 |
| GlyxambiEmpagliflozin/Linagliptin | 31 | $17,406 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $16,229 |
| TrulicityDulaglutide | 12 | $14,527 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $12,134 |
| GemtesaVibegron | 21 | $10,222 |
| VascepaIcosapent Ethyl | 11 | $6,766 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $4,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $698 | $103,728104 claims |
| Novo NordiskOzempic | $1,375 | $99,88571 claims |
| PfizerEliquis | $957 | $83,61999 claims |
| AstraZenecaFarxiga | $1,823 | $62,76747 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $1,249 | $59,98587 claims |
| Lilly USA, LLCMounjaro, Trulicity | $918 | $36,96131 claims |
| MerckJanuvia | $47 | $27,87930 claims |
| Johnson & JohnsonXarelto | $79 | $17,45317 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $183 | $10,22221 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $60 | $1,848155 claims |
| AbbVieSynthroid | $4,427 | $1,71713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.
Other medical in Suffield
- Josephine DiazSuffield$20K
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Alyssa GreenleafSouthington$26K
- Marissa CarignanManchester$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.